BTK and chronic myelogenous leukemia, BCR-ABL1 positive: In a study of four categories of imatinib- and dasatinib-treated patients (imatinib resistant/dasatinib-responsive; dasatinib-resistant; blast crisis or CML progression and T315I or F317L mutated patient receiving omacetaxine treatment) [33], transcriptional and translational levels of HCK, LYN and another SFK-related gene BTK were elevated in more than 50% of resistant CML patients.